|
시장보고서
상품코드
2008034
피부 섬유증(SF) 치료 시장 : 약제 유형별, 투여 경로별, 적응증별, 유통 채널별, 지역별Skin Fibrosis Treatment Market, By Drug Type, By Route of Administration, By Application, By Distribution Channel, By Geography |
||||||
피부 섬유증(SF) 치료 시장은 2026년에 7억 9,600만 달러로 추정되고 있으며, 2033년까지 12억 6,700만 달러에 달할 것으로 예상되고 있습니다. 2026-2033년에는 CAGR 6.9%로 성장할 것으로 전망되고 있습니다.
| 리포트 범위 | 리포트 상세 | ||
|---|---|---|---|
| 기준연도 : | 2025년 | 2026년 시장 규모 : | 7억 9,600만 달러 |
| 과거 데이터 기간 : | 2020-2024년 | 예측 기간 : | 2026-2033년 |
| 2026-2033년의 예측 기간 CAGR : | 6.90% | 2033년 시장 규모 예측 : | 12억 6,700만 달러 |
피부섬유증(SF)은 일반적으로 호산구성 근육통 증후군, 경화성 점액종증(구진성 점액종증), 경화성 부종을 앓고 있는 환자에게서 흔히 발생합니다. 섬유증은 표피와 진피에 손상을 입히는 화학물질에 지속적으로 노출되거나 외상으로 인해 자주 발생합니다. 이는 진피와 피하조직의 섬유성 결합조직의 증가가 특징이며, 종종 지속적인 염증을 동반합니다. 섬유화는 반복적인 화학물질 노출이나 외상으로 인한 표피 또는 진피 손상의 결과로 종종 발생합니다. 진피의 섬유성 결합조직의 증가는 그 특징 중 하나입니다. 다른 많은 장기에도 섬유화를 일으키는 전신성 강피증(SSc, 강피증이라고도 함)은 피부 섬유화를 주요 증상으로 하는 것이 특징입니다. 이 섬유화는 비가역적이지만, 현재 사용 가능한 약물로 어느 정도 치료가 가능합니다. 상처 치유에 대한 병리학적인 반응으로 인한 진피 섬유증은 과도한 피부 흉터입니다. 강피증, 신장성 섬유성 피부병, 혼합성 결합조직병, 강피성 혼합부종, 강피성 부종, 강피성 부종, 호산구성 근막염 등은 존재하는 많은 섬유성 피부질환 중 일부에 불과합니다.
시장 역학
최근 피부 섬유증(SF) 치료의 발전이 확대되면서 예측 기간 중 글로벌 피부 섬유증(SF) 치료 시장의 성장을 촉진할 것으로 예상됩니다. 예를 들어 2017년 12월 Springer Nature가 발표한 데이터에 따르면 새로운 치료 전략이 피부섬유증(SF) 치료에 유망한 결과를 보여주었습니다. 이 치료법에는 모노클로널 항체를 이용한 분자표적치료가 포함됩니다. 리툭시맙(항CD20 항체)과 토실리주맙(항인터류킨-6(IL-6) 수용체 항체)의 경우, 좋은 임상 결과가 보고되고 있습니다.
본 조사의 주요 특징.
- 세계의 피부섬유증(SF) 치료 시장에 대해 조사분석했으며, 2025년을 기준연도로 하여 예측 기간(2026-2033년) 시장 규모와 연평균 성장률(CAGR)을 제시합니다.
- 이 보고서는 각 부문의 잠재적 매출 기회를 밝히고, 이 시장의 매력적인 투자 제안 매트릭스를 설명합니다.
- 또한 시장 촉진요인, 억제요인, 기회, 신제품 출시 및 승인, 시장 동향, 지역별 전망, 주요 기업의 경쟁 전략에 대한 중요 인사이트도 제공합니다.
- 이 보고서에서는 회사 개요, 제품 포트폴리오, 주요 특징, 재무 성과 및 전략과 같은 매개 변수를 기반으로 세계의 피부 섬유증(SF) 치료 시장의 주요 업체를 프로파일링합니다.
- 이 보고서의 내용을 통해 기업의 마케팅 담당자와 경영진은 향후 제품 출시, 제품 업그레이드, 시장 확대, 마케팅 전략에 대한 정보에 입각한 의사결정을 내릴 수 있을 것입니다.
- 이 보고서는 투자자, 공급업체, 제품 제조업체, 유통업체, 신규 진입자, 금융 분석가 등 다양한 이해관계자를 대상으로 합니다.
- 이해관계자들은 세계의 피부섬유증(SF) 치료제 시장 분석에 사용되는 다양한 전략 매트릭스를 통해 의사결정을 쉽게 내릴 수 있을 것입니다.
목차
제1장 조사 목적과 전제조건
제2장 시장 범위
제3장 시장 역학, 규제 및 동향 분석
제4장 세계의 피부 섬유증(SF) 치료 시장 : 약제 유형별, 2020-2033년
제5장 세계의 피부 섬유증(SF) 치료제 시장 : 투여 경로별, 2020-2033년
제6장 세계의 피부 섬유증(SF) 치료 시장 : 적응증별, 2020-2033년
제7장 세계의 피부 섬유증(SF) 치료 시장 : 유통 채널별, 2020-2033년
제8장 세계의 피부 섬유증(SF) 치료 시장 : 지역별, 2020-2033년
제9장 경쟁 구도
제10장 섹션
KSA 26.04.30Skin Fibrosis Treatment Market is estimated to be valued at USD 796 Mn in 2026 and is expected to reach USD 1,267 Mn by 2033, growing at a compound annual growth rate (CAGR) of 6.9% from 2026 to 2033.
| Report Coverage | Report Details | ||
|---|---|---|---|
| Base Year: | 2025 | Market Size in 2026: | USD 796 Mn |
| Historical Data for: | 2020 To 2024 | Forecast Period: | 2026 To 2033 |
| Forecast Period 2026 to 2033 CAGR: | 6.90% | 2033 Value Projection: | USD 1,267 Mn |
Skin fibrosis generally occurs in patients who suffer from eosinophilia-myalgia syndrome, scleromyxedema (papular mucinosis) and scleredema. Fibrosis frequently develops as a result of continuous chemical exposure or trauma that causes epidermal or dermal harm. It is characterized by an increase of fibrous connective tissues in the dermis or subcutis and frequently goes hand in hand with persistent inflammation. Fibrosis frequently develops as a result of epidermal or dermal damage brought on by repeated chemical exposure or trauma. An increase in fibrous connective tissues in the dermis is one of its defining features. Systemic sclerosis (SSc also known as scleroderma), which also causes fibrosis in a number of other organs, is characterized by the primary symptom of skin fibrosis. Although, this fibrosis cannot be reversed, it can be treated to some extent using currently available drugs. Dermal fibrosis, which results from a pathologic reaction to wound healing, is excessive skin scarring. Scleroderma, nephrogenic fibrosing dermopathy, mixed connective tissue disease, scleromyxedema, scleredema, and eosinophilic fasciitis are only a few of the many fibrotic skin illnesses that exist.
Market Dynamics
The rise in recent advances in treatment for the skin fibrosis is expected to drive the global skin fibrosis treatment market growth over the forecast period. For instance, in December 2017, according to the data published by the Springer Nature, the new treatment strategy has shown promising results in the treatment of skin fibrosis. The treatment involves the molecular targeting therapy with monoclonal antibody. The positive clinical outcomes had been reported in rituximab (an anti-CD20 antibody) and the tocilizumab (an anti-interleukin-6 (IL-6) receptor antibody).
Key features of the study
- This report provides an in-depth analysis of the global skin fibrosis treatment market, and provides market size (USD Mn) and compound annual growth rate (CAGR%) for the forecast period (2026-2033), considering 2025 as the base year
- It elucidates potential revenue opportunities across different segments and explains attractive investment proposition matrices for this market
- This study also provides key insights about market drivers, restraints, opportunities, new product launches or approval, market trends, regional outlook, and competitive strategies adopted by key players
- It profiles key players in the global skin fibrosis treatment market based on the following parameters - company highlights, products portfolio, key highlights, financial performance, and strategies
- Key companies covered as a part of this study include Pharmaxis, Jubilant Cadista, Horizon Pharma USA, Pfizer, Sanofi, F. Hoffmann-La Roche, Boehringer Ingelheim, , Bristol-Myers Squibb Company
- Insights from this report would allow marketers and the management authorities of the companies to make informed decisions regarding their future product launches, type up-gradation, market expansion, and marketing tactics
- The global skin fibrosis treatment market report caters to various stakeholders in this industry including investors, suppliers, product manufacturers, distributors, new entrants, and financial analysts
- Stakeholders would have ease in decision-making through various strategy matrices used in analyzing the global skin fibrosis treatment market
Skin Fibrosis Treatment Market Segmentation
- By Drug Type Insights (Revenue, USD Mn, 2020 - 2033)
- Corticosteroids
- Antifibrotic Drugs
- Immunotherapy Drugs
- Other (Immunosuppressant)
- By Route of Administration Insights (Revenue, USD Mn, 2020 - 2033)
- Oral
- Parenteral
- Other (Topical)
- By Application Insights (Revenue, USD Mn, 2020 - 2033)
- Localized forms of scleroderma
- Eosinophilic fasciitis
- Scleromyxedema (papular mucinosis)
- Scleredema
- By Distribution Channel Insights (Revenue, USD Mn, 2020 - 2033)
- Hospital Pharmacies
- Retail Pharmacies
- Online Pharmacies
- By Region Insights (Revenue, USD Mn, 2020 - 2033)
- North America
- U.S.
- Canada
- Latin America
- Brazil
- Argentina
- Mexico
- Rest of Latin America
- Europe
- Germany
- U.K.
- Spain
- France
- Italy
- Russia
- Rest of Europe
- Asia Pacific
- China
- India
- Japan
- Australia
- South Korea
- ASEAN
- Rest of Asia Pacific
- Middle East & Africa
- GCC Countries
- Israel
- Rest of Middle East & Africa
- Key Players in the Skin Fibrosis Treatment Market
- Pharmaxis
- Jubilant Cadista
- Horizon Pharma USA
- Pfizer, Sanofi
- Hoffmann-La Roche
- Boehringer Ingelheim
- Bristol-Myers Squibb Company
Table of Contents
1. Research Objectives and Assumptions
- Research Objectives
- Assumptions
- Abbreviations
2. Market Purview
- Report Description
- Market Definition and Scope
- Executive Summary
- Market Snapshot, By Drug Type
- Market Snapshot, By Route of Administration
- Market Snapshot, By Application
- Market Snapshot, By Distribution Channel
- Market Snapshot, By Region
- Coherent Opportunity Map (COM)
3. Market Dynamics, Regulations, and Trends Analysis
- Market Dynamics
- Drivers
- Restraints
- Market Opportunities
- Impact Analysis
- Market Trends
- Recent Developments
- Acquisitions and Partnerships Scenario
- Technology Overview
- Regulatory Scenario
- Pricing Analysis
- PEST Analysis
4. Global Skin Fibrosis Treatment Market, By Drug Type, 2020 - 2033, (USD Mn)
- Overview
- Market Share Analysis, 2026 and 2033 (%)
- Y-o-Y Growth Analysis, 2020 - 2033
- Segment Trends
- Corticosteroids
- Overview
- Market Size and Forecast, and Y-o-Y Growth, 2020-2033, (USD Mn)
- Antifibrotic Drugs
- Overview
- Market Size and Forecast, and Y-o-Y Growth, 2020-2033, (USD Mn)
- Immunotherapy Drugs
- Overview
- Market Size and Forecast, and Y-o-Y Growth, 2020-2033, (USD Mn)
- Other (Immunosuppressant)
- Overview
- Market Size and Forecast, and Y-o-Y Growth, 2020-2033, (USD Mn)
5. Global Skin Fibrosis Treatment Market, By Route of Administration, 2020 - 2033, (USD Mn)
- Overview
- Market Share Analysis, 2026 and 2033 (%)
- Y-o-Y Growth Analysis, 2020 - 2033
- Segment Trends
- Oral
- Overview
- Market Size and Forecast, and Y-o-Y Growth, 2020-2033, (USD Mn)
- Parenteral
- Overview
- Market Size and Forecast, and Y-o-Y Growth, 2020-2033, (USD Mn)
- Other (Topical)
- Overview
- Market Size and Forecast, and Y-o-Y Growth, 2020-2033, (USD Mn)
6. Global Skin Fibrosis Treatment Market, By Application, 2020 - 2033, (USD Mn)
- Overview
- Market Share Analysis, 2026 and 2033 (%)
- Y-o-Y Growth Analysis, 2020 - 2033
- Segment Trends
- Localized forms of scleroderma
- Overview
- Market Size and Forecast, and Y-o-Y Growth, 2020-2033, (USD Mn)
- Eosinophilic fasciitis
- Overview
- Market Size and Forecast, and Y-o-Y Growth, 2020-2033, (USD Mn)
- Scleromyxedema (papular mucinosis)
- Overview
- Market Size and Forecast, and Y-o-Y Growth, 2020-2033, (USD Mn)
- Scleredema
- Overview
- Market Size and Forecast, and Y-o-Y Growth, 2020-2033, (USD Mn)
7. Global Skin Fibrosis Treatment Market, By Distribution Channel, 2020 - 2033, (USD Mn)
- Overview
- Market Share Analysis, 2026 and 2033 (%)
- Y-o-Y Growth Analysis, 2020 - 2033
- Segment Trends
- Hospital Pharmacies
- Overview
- Market Size and Forecast, and Y-o-Y Growth, 2020-2033, (USD Mn)
- Retail Pharmacies
- Overview
- Market Size and Forecast, and Y-o-Y Growth, 2020-2033, (USD Mn)
- Online Pharmacies
- Overview
- Market Size and Forecast, and Y-o-Y Growth, 2020-2033, (USD Mn)
8. Global Skin Fibrosis Treatment Market, By Region, 2020 - 2033, (USD Mn)
- Introduction
- Market Share Analysis, By Region, 2026 and 2033 (%)
- Y-o-Y Growth Analysis, For Regions, 2020-2033
- Regional Trends
- North America
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, By Drug Type, 2020 - 2033, (USD Mn)
- Market Size and Forecast, and Y-o-Y Growth, By Route of Administration, 2020 - 2033, (USD Mn)
- Market Size and Forecast, and Y-o-Y Growth, By Application, 2020 - 2033, (USD Mn)
- Market Size and Forecast, and Y-o-Y Growth, By Distribution Channel, 2020 - 2033, (USD Mn)
- Market Size and Forecast, and Y-o-Y Growth, By Country, 2020 - 2033, (USD Mn)
- U.S.
- Canada
- Latin America
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, By Drug Type, 2020 - 2033, (USD Mn)
- Market Size and Forecast, and Y-o-Y Growth, By Route of Administration, 2020 - 2033, (USD Mn)
- Market Size and Forecast, and Y-o-Y Growth, By Application, 2020 - 2033, (USD Mn)
- Market Size and Forecast, and Y-o-Y Growth, By Distribution Channel, 2020 - 2033, (USD Mn)
- Market Size and Forecast, and Y-o-Y Growth, By Country, 2020 - 2033, (USD Mn)
- Brazil
- Mexico
- Argentina
- Rest of Latin America
- Europe
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, By Drug Type, 2020 - 2033, (USD Mn)
- Market Size and Forecast, and Y-o-Y Growth, By Route of Administration, 2020 - 2033, (USD Mn)
- Market Size and Forecast, and Y-o-Y Growth, By Application, 2020 - 2033, (USD Mn)
- Market Size and Forecast, and Y-o-Y Growth, By Distribution Channel, 2020 - 2033, (USD Mn)
- Market Size and Forecast, and Y-o-Y Growth, By Country, 2020 - 2033, (USD Mn)
- U.K.
- Germany
- Italy
- France
- Spain
- Russia
- Rest of Europe
- Asia Pacific
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, By Drug Type, 2020 - 2033, (USD Mn)
- Market Size and Forecast, and Y-o-Y Growth, By Route of Administration, 2020 - 2033, (USD Mn)
- Market Size and Forecast, and Y-o-Y Growth, By Application, 2020 - 2033, (USD Mn)
- Market Size and Forecast, and Y-o-Y Growth, By Distribution Channel, 2020 - 2033, (USD Mn)
- Market Size and Forecast, and Y-o-Y Growth, By Country, 2020 - 2033, (USD Mn)
- China
- India
- Japan
- ASEAN
- Australia
- South Korea
- Rest of Asia Pacific
- Middle East
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, By Drug Type, 2020 - 2033, (USD Mn)
- Market Size and Forecast, and Y-o-Y Growth, By Route of Administration, 2020 - 2033, (USD Mn)
- Market Size and Forecast, and Y-o-Y Growth, By Application, 2020 - 2033, (USD Mn)
- Market Size and Forecast, and Y-o-Y Growth, By Distribution Channel, 2020 - 2033, (USD Mn)
- Market Size and Forecast, and Y-o-Y Growth, By Country, 2020 - 2033, (USD Mn)
- GCC
- Israel
- Rest of Middle East
- Africa
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, By Drug Type, 2020 - 2033, (USD Mn)
- Market Size and Forecast, and Y-o-Y Growth, By Route of Administration, 2020 - 2033, (USD Mn)
- Market Size and Forecast, and Y-o-Y Growth, By Application, 2020 - 2033, (USD Mn)
- Market Size and Forecast, and Y-o-Y Growth, By Distribution Channel, 2020 - 2033, (USD Mn)
- Market Size and Forecast, and Y-o-Y Growth, By Country, 2020 - 2033, (USD Mn)
- North Africa
- Central Africa
- South Africa
9. Competitive Landscape
- Pharmaxis
- Company Highlights
- Product Portfolio
- Key Highlights
- Financial Performance
- Market Strategies
- Jubilant Cadista
- Company Highlights
- Product Portfolio
- Key Highlights
- Financial Performance
- Market Strategies
- Horizon Pharma USA
- Company Highlights
- Product Portfolio
- Key Highlights
- Financial Performance
- Market Strategies
- Pfizer
- Company Highlights
- Product Portfolio
- Key Highlights
- Financial Performance
- Market Strategies
- Sanofi
- Company Highlights
- Product Portfolio
- Key Highlights
- Financial Performance
- Market Strategies
- F. Hoffmann-La Roche
- Company Highlights
- Product Portfolio
- Key Highlights
- Financial Performance
- Market Strategies
- Boehringer Ingelheim
- Company Highlights
- Product Portfolio
- Key Highlights
- Financial Performance
- Market Strategies
- Bristol-Myers Squibb Company
- Company Highlights
- Product Portfolio
- Key Highlights
- Financial Performance
- Market Strategies
10. Section
- Research Methodology
- About Us
